The S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) hasn’t been able to follow up on yesterday’s gains and afternoon trade has fallen 0.3% to 5,742 points. Today’s decline is largely down to steep declines in the utilities and materials sectors.
Four shares which have gone against the grain today and jumped higher are listed below. Here’s why they’ve surged higher:
The Bubs Australia Ltd (ASX: BUB) share price is up almost 11% to 10.5 cents after the infant formula and baby food company announced a supply agreement with retail giant Costco. The deal will see Costco offer Bubs infant formula products in its wholesale catalogue nationally and at one of its warehouses in Sydney.
The Capitol Health Ltd (ASX: CAJ) share price has jumped almost 7% to 16 cents despite there being no news out of the diagnostic imaging company. Capitol Health recently raised $38.5 million in order to reduce its debt levels. Management believes the improved balance sheet now provides it with a platform for growth.
The Impedimed Limited (ASX: IPD) share price has followed up on yesterday’s rise with a 3.5% gain to 72.5 cents. Investors have been snapping up the medical device company’s shares after it announced that its first SOZO device had been placed with Scripps Health in the United States. Management is targeting the chronic heart failure market which impacts an estimated 5.7 million people in the country.
The Mesoblast limited (ASX: MSB) share price has also climbed for a second day in a row, this time by 3.5% to $2.01. Yesterday the U.S. Food and Drug Administration granted its MSC-100-IV cell therapy fast-track status. This has the potential to shorten the time to FDA approval. So much so management appears confident that a single successful open-label Phase 3 trial will be sufficient for conditional FDA approval. Whilst this is promising news, I feel it is a little early for an investment.
Finally, if you missed out on gains today don't worry. I think these hot growth stocks will be big winners this year.
For many, blue chip stocks means stability, profitability and regular dividends, often full franked..
But knowing which blue chips to buy, and when, can often be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2017."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
If you’re expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you’ll be sorely disappointed. Not only are their dividends growing at a snail’s pace, their profits are under pressure too due to the increasing competitive environment.
The contrast to these “new breed” blue chips couldn’t be greater… especially the very real prospect of significant share price gains, something that’s looking less likely from the usual blue chip suspects.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.